remdesivir / Generic mfg. - LARVOL DELTA

Administration of antivirals, IL-6 inhibitors, monoclonal neutralizing antibodies and systemic corticosteroids in acute SARS-CoV-2 infection do not reduce the subsequent burden of Long-COVID symptoms. (PubMed, Infez Med) - "Treatments administered during acute phase included systemic steroids (52.8%), antivirals (20.7%, mostly remdesivir), IL-6 inhibitors (9.4%) and neutralizing antibodies (3.9%)...Some drug classes showed a protective effect that was however not confirmed in multivariable analyses, underlining the importance of adjusting for a comprehensive number of covariates. Clinicians should consider the possibility that systemic corticosteroids and IL-6 inhibitors administered during acute COVID-19 may prolong the persistence of particular symptoms."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes. (PubMed, J Antimicrob Chemother) - "Economic data from this study of elderly adults with mild-moderate COVID-19 suggest that addition of NMV/r to hospital formulary should be considered to support optimal resources consumption, while the clinical impact of NMV/r availability may be better studied through evaluating mild or moderate COVID-19 disease independently."

Clinical data • Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease

Post-exposure prevention in Marburg virus outbreaks: potential role of remdesivir in emergency response. (PubMed, Ann Med Surg (Lond)) - "Nevertheless, its integration into emergency protocols, accompanied by investments in research, early authorizations, and strategic stockpiles, could strengthen response capacities. While awaiting a vaccine, each antiviral option deserves rigorous attention to limit transmission and mortality during future Marburg outbreaks."

Journal • Ebola Virus Disease • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Group-Sequential Designs With an Externally-Driven Change of Primary Endpoint. (PubMed, Stat Med) - "The method is illustrated using a simulated data example based on a clinical trial of remdesivir in COVID-19. Construction of critical values for the test of the new primary endpoint require a value for the correlation between this and the initial primary endpoint. We present simulation studies to demonstrate that the type I error rate is controlled when this value is estimated from the data on the two endpoints obtained from the trial."

Journal • Infectious Disease • Novel Coronavirus Disease

Successful remdesivir treatment of coronavirus OC43 pneumonia in a lung transplant recipient. (PubMed, J Chemother) - "New treatment options are needed even to prevent complications, such as acute rejection. This clinical case suggests remdesivir could have a role in non-SARS-CoV-2 coronavirus infections."

Journal • Cough • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Transplant Rejection • Transplantation

Comparing the clinical outcomes of Remdesivir and Interferon beta-1a in hospitalized COVID-19 patients: A cross-sectional retrospective single-center study. (PubMed, J Infect Dev Ctries) - "No difference in clinical outcomes was found between RDV and IFNβ-1a treatments. RDV was more effective than IFNβ-1a in moderating the inflammatory response in COVID-19 patients by reducing LDH and ESR. The IFNβ-1a group had a considerably lower rate of ICU admission than the RDV group."

Clinical • Clinical data • Journal • Retrospective data • Cough • Critical care • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • IFNB1

NEO100 facilitates delivery of blood-brain barrier impenetrable drugs (SNO 2025) - "We have shown that NEO100 significantly enhances the brain tumor specific uptake and retention of doxorubicin, dexamethasone, and remdesivir when administered via an intra-nasal route in a formulation that contains NEO100 at concentrations as low as 1%, when compared to traditional oral or IV routes of administration. Understanding how NEO100 functions in manipulating the barrier's physiology is crucial for developing next-generation therapeutics capable of treating CNS diseases effectively. Continued innovation in drug design and delivery technologies is essential for expanding the range of treatable neurological conditions"

Brain Cancer • CNS Disorders • Glioma • Solid Tumor

Remdesivir and Renal Outcomes in Hospitalized COVID-19 Patients Without Severe Renal Impairment: A Retrospective Cohort Study. (PubMed, Ann Pharmacother) - "Remdesivir use was not associated with increased or reduced risk of RAEs in hospitalized COVID-19 patients without severe renal impairment, thereby supporting its continued clinical use as a safe antiviral without offering additional renal benefit."

Journal • Retrospective data • Acute Kidney Injury • Infectious Disease • Nephrology • Novel Coronavirus Disease • Renal Disease

Survival analysis of drug effectiveness of remdesivir and dexamethasone for confirmed COVID-19 patients using Japanese medical claim data. (PubMed, Int J Infect Dis) - "Findings indicate that remdesivir and dexamethasone might not contribute to saving life among patients with oxygen administration. No drug increased or reduced the probability of saving life among patients who were treated with ventilation."

Journal • Infectious Disease • Novel Coronavirus Disease

Profile of clinical trials with drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Spain. (PubMed, Farm Hosp) - "We conclude that there is a need to improve transparency, record all results- including negative ones- and review key aspects of design and funding, as recommendations for future research, including in health emergencies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical Outcomes of COPD Patients Hospitalized for SARS-Cov-2 Infection During the Omicron Era: Comparative Effectiveness of Initiating Remdesivir in Addition to Corticosteroids Versus Corticosteroids Alone. (PubMed, Viruses) - "The combination of RDV and CCS was also associated with a lower mortality risk at 14 and 28 days for patients across baseline oxygen requirements compared to CCS only. These results highlight the benefit of timely RDV treatment in COPD patients hospitalized with SARS-CoV-2 infection and underscore the value of considering established treatment paradigms in the context of the most recent collective evidence."

Clinical • Clinical data • HEOR • Journal • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Elevated Troponin, D-Dimers and D-Dimers/Fibrinogen Ratio Increase Mortality Risk in Remdesivir-Treated COVID-19 Patients. (PubMed, J Pers Med) - " In addition to its antiviral action, remdesivir treatment was associated with changes in coagulation biomarkers, potentially preventing patients from the COVID-19-provoked hypercoagulable state. Troponin, D-dimers, and DFR hold a critical role in predicting mortality risk among COVID-19 patients treated with remdesivir and can aid in identifying individuals at increased risk of death."

Journal • Infectious Disease • Novel Coronavirus Disease

Impact of COVID-19 therapeutics on the development of post-infectious lung fibrosis. (PubMed, Front Microbiol) - "Remdesivir use was significantly associated with a reduced risk of PCPF (aOR: 0.359; 95% CI: 0.176-0.734; p = 0.005), whereas baricitinib use was associated with an increased risk (aOR: 5.633; 95% CI: 1.642-19.548; p = 0.006). Although adjusted for multiple confounders, residual indication bias of each treatment cannot be completely excluded. Therefore, prospective studies are needed to validate these associations."

Journal • Fibrosis • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases

Template switching by coronavirus polymerase requires helicase activity and is stimulated by remdesivir and molnupiravir. (PubMed, bioRxiv) - "We propose a novel mechanism of action where incorporation of these analogs dramatically reduces full length genome copy number by stimulating polymerase template switching. Our study further demonstrates nsp13-helicase's central role in CoV replication and how this enzyme function can be indirectly targeted by analogs."

Journal • Infectious Disease • Novel Coronavirus Disease

Structural basis for selective remdesivir incorporation by SARS-CoV-2 polymerase, and S759A resistance. (PubMed, Res Sq) - "The structures of S759A RdRp reveal that the primer 3'-end nucleotide repositioning and its altered ribose-ring conformation contribute to RTP resistance. These findings have implications for designing non-obligate nucleoside analogs with different inhibition mechanisms."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Identification and characterization of a SARS-CoV-2 M pro G23 deletion ensitrelvir-resistant mutant. (PubMed, bioRxiv) - "The clinical use of SARS-CoV-2 antiviral drugs is increasingly challenged by the emergence of drug-resistant mutants. Thus, there is a pressing need to identify and characterize antiviral escape SARS-CoV-2 variants, particularly for FDA-approved antivirals. Our study addresses this by employing a luminescent attenuated virus platform (Δ3a7b-Nluc WT) to safely identify and characterize resistance mutations without the concern of using virulent forms of SARS-CoV-2. Using this safe approach, we have identified a G23 deletion (G23del) in SARS-CoV-2 M pro , which mediates resistance to ensitrelvir in vitro and in vivo . Importantly, while G23del was able to confer more than 1,000-fold increased resistance to ensitrelvir, SARS-CoV-2 containing G23del remained sensitive to other M pro (nirmatrelvir) and RdRp (remdesivir) inhibitors. Altogether, this study demonstrates the feasibility of using Δ3a7b-Nluc to safely identify and characterize drug resistant viruses without the..."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • SPECC1

Integrated computational approach revealed the potential inhibitory effect of xanthone derivatives against Marburg virus nucleocapsid. (PubMed, Virusdisease) - "Molecular docking revealed that Magniferin showed the highest binding affinity (-7.0 kcal/mol) among the selected phytocompounds, outperforming the reference drug Remdesivir (-5.0 kcal/mol)...These findings suggest that Magniferin could serve as a promising lead compound for the development of MARV therapeutics. The online version contains supplementary material available at 10.1007/s13337-025-00933-x."

Journal

Allosteric Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase Based on N,N'-Diphenylurea. (PubMed, ChemMedChem) - "To date, only a few such agents, including molnupiravir and remdesivir, have been approved by the FDA. Despite these improvements, cytotoxicity remains a limitation across the series. These findings provide valuable structure-activity relationship insights and direct ongoing optimization efforts toward developing less toxic, soluble RdRp inhibitors with improved antiviral profiles."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

NEO100 facilitates delivery of blood-brain barrier impenetrable drugs (WFNOS 2025) - "We have shown that NEO100 significantly enhances the brain tumor specific uptake and retention of doxorubicin, dexamethasone, and remdesivir when administered via an intra-nasal route in a formulation that contains NEO100 at concentrations as low as 1%, when compared to traditional oral or IV routes of administration. Understanding how NEO100 functions in manipulating the barrier's physiology is crucial for developing next-generation therapeutics capable of treating CNS diseases effectively. Continued innovation in drug design and delivery technologies is essential for expanding the range of treatable neurological conditions"

Brain Cancer • CNS Disorders • Solid Tumor

Clinical Profile and Outcomes of COVID-19 Patients in Acute Respiratory Distress Syndrome (ARDS) in a Tertiary Hospital in Baguio City: A Retrospective Cross-Sectional Study (APSR 2025) - "Conclusion : This study determined that mortality rate was higher in patients with CAD, Hypertension, Type 2 Diabetes Mellitus and Chronic Kidney Disease, with CAD associated with highest likelihood for worse outcome and death. The use of High Flow Nasal Cannula was associated with a mortality reduction, given with other therapeutic regimens Dexamethasone and Remdesivir."

Observational data • Retrospective data • Acute Respiratory Distress Syndrome • Cardiovascular • Chronic Kidney Disease • Diabetes • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection. (PubMed, J Med Virol) - "Unlike many candidates that faltered in complex models, Azatadine-Dimaleate maintained efficacy across all platforms. These findings support its clinical evaluation, alone or in combination with Remdesivir, as a versatile therapeutic with strong potential to address current and emerging SARS-CoV-2 variants."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL6

Genetic determinants of efficacy of antiviral drugs revealed by genome-wide CRISPR screens. (PubMed, Antiviral Res) - "For ribavirin, adenosine kinase (ADK) and adenylsuccinate synthase (ADSS) were critical for nucleotide metabolism and bioactivation. Remdesivir uptake and activation depended on the transporter SLC29A3 and phosphoamidase HINT1, whereas favipiravir resistance was linked to NT5C2-mediated dephosphorylation. Viral replication assays in Huh7 cells validated that knockout of SLC29A3, HINT1, or NT5C2 significantly altered antiviral efficacy. This study delineates the genetic network governing nucleotide analog response, providing mechanistic insights and potential biomarkers for personalized antiviral therapy."

Journal • Hematological Malignancies • Lymphoma • Oncology • HINT1 • NT5C2

Successful treatment and long-term follow-up of a young cat with feline infectious peritonitis and renal lymphoma. (PubMed, Open Vet J) - "A modified Cyclophosphamide, vincristine and prednisolone protocol with vinblastine addition (Cyclophosphamide, vincristine, prednisolone and vinblastine protocol) was started, resulting in a complete response...Subcutaneous administration of GS441524 led to FIP resolution...To the author's knowledge, this is the first case of renal lymphoma in a cat that subsequently developed FIP. Further studies on the potential correlation between lymphoma, chemotherapy, and FIP are needed."

Journal • Anorexia • Hematological Malignancies • Lymphoma • Oncology • Respiratory Diseases

Refractory pneumonia due to persistent SARS-CoV-2 infection in an immunocompromised host successfully treated with extended course nirmatrelvir/ritonavir. (PubMed, ASM Case Rep) - "Despite repeated remdesivir and glucocorticoid therapy, her respiratory symptoms worsened and progressed to respiratory failure. The genome analysis indicated that genomic mutations accumulate due to continuous XBB infection. The patient recovered after treatment with nirmatrelvir/ritonavir for 20 days."

Journal • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases

Integrative Machine Learning and Bayesian Analysis Reveals Atrial Fibrillation as a Key Predictor of Severe COVID-19 Outcomes. (PubMed, Clin Transl Sci) - "This study aimed to identify predictors of critical outcomes, including mortality, in hospitalized COVID-19 patients treated with remdesivir, using statistical, machine learning, and Bayesian methods...Bayesian analysis confirmed a strong association between atrial fibrillation and adverse outcomes (adjusted OR 5.121). Atrial fibrillation emerged as a consistent and strong predictor, underscoring its relevance in clinical risk assessment."

Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Infectious Disease • Nephrology • Novel Coronavirus Disease • Renal Disease